Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | THRA | P10827 | 2/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | ATF4 | P18848 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734827 | 0.98 | THRA (0.42) | ITGB3ITGA2BTHRBTHRAPTGIR | |
| SCHEMBL15159536 | 0.98 | THRA (0.42) | ITGB3ITGA2BTHRBTHRAPTGIR | |
| SCHEMBL9132526 | 0.98 | THRA (0.42) | ITGB3ITGA2BTHRBTHRAPTGIR | |
| SCHEMBL16204628 | 0.98 | THRA (0.42) | ITGB3ITGA2BTHRBTHRAPTGIR | |
| SCHEMBL27451178 | 0.98 | THRA (0.42) | ITGB3ITGA2BTHRBTHRAPTGIR | |
| SCHEMBL24564741 | 0.98 | THRA (0.42) | ITGB3ITGA2BTHRBTHRAPTGIR | |
| SCHEMBL1733927 | 0.95 | — | — | |
| SCHEMBL9194978 | 0.90 | — | — | |
| SCHEMBL11918037 | 0.83 | ITGB3 (0.38) | ITGB3ITGA2BTHRBTHRAPTGIR | |
| SCHEMBL432285 | 0.83 | ITGB3 (0.38) | ITGB3ITGA2BTHRBTHRAPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| CN-114671864-B | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240400562-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4419509-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118339149-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-1288280-B1 | Use of tertiary alcohols or esters as perfuming ingredients | FIRMENICH & CIE (CH) | 2007-01-03 | — | — | EP | disclosed |
| CN-1184214-C | Alpha-acyl and alpha-heteroatom substituted phenylacetamide glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-01-12 | — | — | CN | disclosed |
| US-6720295-B2 | COMPOUND CONTAINING CYCLOPENT(EN)YL RING | FIRMENICH SA (CH) | 2004-04-13 | — | — | US | disclosed |
| CN-1443177-A | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | CN | disclosed |
| US-20030087775-A1 | Use of tertiary alcohols or esters as perfuming ingredients | FIRMENICH SA (CH) | 2003-05-08 | — | — | US | disclosed |
| EP-1288280-A2 | Use of tertiary alcohols or esters as perfuming ingredients | FIRMENICH SA (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-4735932-A | ORGANOLEPTIC | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1988-04-05 | — | — | US | disclosed |
| US-4735932-A | ORGANOLEPTIC | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1988-04-05 | — | — | US | disclosed |
| US-4735932-A | ORGANOLEPTIC | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1988-04-05 | — | — | US | disclosed |
| CN-85107017-A | Preparation three ring pyridazinones dihydro compounds and the method that contains the pharmaceutical composition of this compound | — | 1987-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400562-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR6 | ITGB3 2847/4885ITGA2B 2410/4885THRB 1199/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | ITGB3 672/4885ITGA2B 243/4885THRB 3265/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | ITGB3 2718/4885ITGA2B 3184/4885THRB 861/4885 |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRB1 | ITGB3 922/4885ITGA2B 771/4885THRB 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.